It's accretive for Novartis, but very accretive for Roche," said Jefferies' analyst Jeff Holford. . 
Share:  <span class="sent">It's accretive for Novartis, but very accretive for <span class="company">Roche</span>," said Jefferies' analyst <span class="analyst">Jeff Holford</span>. .</span> Tweet this   read full story

Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased competition and reimbursement pressure. 
Share:  <span class="sent">Swiss drugmaker Roche Holding AG is exploring a sale of its blood glucose meters business, three people familiar with the matter told Reuters on Wednesday, as the industry grapples with increased competition and reimbursement pressure.</span> Tweet this   read full story

First quarter sales of Brilinta , a heart drug which AstraZeneca had hoped to become a blockbuster , rose only modestly in the quarter, bringing in $51 million rather than $38 million in the last quarter of 2012. Soriot told investors: "We remain focused on our strategic priorities of returning to growth and achieving scientific leadership." But he admitted this year sales are expected to fall by a "mid to high single digit percentage". 
Share:  First quarter sales of Brilinta , a heart drug which AstraZeneca had hoped to become a blockbuster , rose only modestly in the quarter, bringing in $51 million rather than $38 million in the last quarter of 2012. <span class="sent"><span class="analyst">Soriot</span> told investors: "We remain focused on our strategic priorities of returning to growth and achieving scientific leadership."</span> But he admitted this year sales are expected to fall by a "mid to high single digit percentage". Tweet this   read full story